Impact Factor 3.113 | CiteScore 3.03
More on impact ›

Original Research ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Med. | doi: 10.3389/fmed.2019.00237

Low expression of 14-3-3beta is associated with adverse survival of diffuse large B-cell lymphoma patients

 Chaoping Li1, zhaoming li1 and  Mingzhi Zhang1*
  • 1First Affiliated Hospital of Zhengzhou University, China

Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin's lymphoma in the world, is highly heterogeneous. Although current therapies have improved the clinical outcome, 30–40% of the patients are still not cured. Thus, novel treatment options such as targeted therapy is urgently needed.
Accumulating evidence suggests that 14-3-3beta protein plays an important role in tumorigenesis and tumor progression. However, the specific roles of 14-3-3beta in DLBCL are still poorly understood. In this study, we retrospectively analyzed 120 archived wax blocks obtained from patients with DLBCL (n=70) and non-neoplastic lymph nodes (n=50). Immunohistochemical staining showed that 14-3-3beta gene expression was significantly decreased in DLBCL tissues (P < 0.001) compared to that in non-neoplastic lymph nodes. Low 14-3-3beta expression was significantly correlated with extra-nodal status (P=0.026), serum LDH level (P=0.023) and adverse survival of DLBCL patients. In survival analyses, low 14-3-3beta expression was significantly associated with adverse overall survival of the DLBCL patients (P=0.003). Using the Kaplan-Meier analysis module of the R2 microarray analysis and visualization platform (, we also confirmed that low expression of 14-3-3beta gene had inferior overall survival in DLBCL patients.
Based on our results, we conclude that low expression of 14-3-3beta is associated with adverse survival of diffuse large B-cell lymphoma patients, suggesting a novel prognostic marker and potential therapeutic target.

Keywords: 14-3-3beta, Diffuse large B-cell lymphoma (DLBCL), Immunohistochemistry, Kaplan-Meier analysis, targeted therapy

Received: 16 Aug 2019; Accepted: 10 Oct 2019.

Copyright: © 2019 Li, li and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Prof. Mingzhi Zhang, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China,